{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:18:01Z","timestamp":1780431481852,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R15ES026789"],"award-info":[{"award-number":["R15ES026789"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"national institute of general medical sciences","doi-asserted-by":"crossref","award":["P20GM121322-03"],"award-info":[{"award-number":["P20GM121322-03"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012639","name":"metavivor","doi-asserted-by":"publisher","award":["1008553R"],"award-info":[{"award-number":["1008553R"]}],"id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"name":"mylan chair endowment fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00204-021-03147-4","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:02:33Z","timestamp":1630166553000},"page":"3575-3587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo"],"prefix":"10.1007","volume":"95","author":[{"given":"Zhongwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Sprowls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkar","family":"Saralkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroz","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Blethen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem A.","family":"Arsiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Fladeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-3258","authenticated-orcid":false,"given":"Weimin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"issue":"12","key":"3147_CR1","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1158\/1535-7163.MCT-09-0685","volume":"8","author":"T Akiyama","year":"2009","unstructured":"Akiyama T, Dass CR, Choong PF (2009) Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 8(12):3173\u20133180","journal-title":"Mol Cancer Ther"},{"key":"3147_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/940585","volume":"2012","author":"JT Alander","year":"2012","unstructured":"Alander JT, Kaartinen I, Laakso A et al (2012) A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging 2012:940585. https:\/\/doi.org\/10.1155\/2012\/940585","journal-title":"Int J Biomed Imaging"},{"issue":"1","key":"3147_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74746-x","volume":"10","author":"Z Areeb","year":"2020","unstructured":"Areeb Z, Stuart SF, West AJ et al (2020) Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep 10(1):1\u201312","journal-title":"Sci Rep"},{"key":"3147_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/OTT.S129809","volume":"10","author":"H Bai","year":"2017","unstructured":"Bai H, Xiong L, Han B (2017) The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. Onco Targets Ther 10:2335\u20132340. https:\/\/doi.org\/10.2147\/OTT.S129809","journal-title":"Onco Targets Ther"},{"issue":"9","key":"3147_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/JTO.0000000000000615","volume":"10","author":"CS Baik","year":"2015","unstructured":"Baik CS, Chamberlain MC, Chow LQ (2015) Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 10(9):1268\u20131278. https:\/\/doi.org\/10.1097\/JTO.0000000000000615","journal-title":"J Thorac Oncol"},{"issue":"20","key":"3147_CR6","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z et al (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22(20):5130\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3147_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.lungcan.2013.02.004","volume":"80","author":"LA Berger","year":"2013","unstructured":"Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D (2013) CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80(3):242\u2013248","journal-title":"Lung Cancer"},{"key":"3147_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2017.00193","volume":"8","author":"KA Bohn","year":"2017","unstructured":"Bohn KA, Adkins CE, Nounou MI, Lockman PR (2017) Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol 8:193. https:\/\/doi.org\/10.3389\/fphar.2017.00193","journal-title":"Front Pharmacol"},{"issue":"1","key":"3147_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-012-0990-5","volume":"111","author":"F Burel-Vandenbos","year":"2013","unstructured":"Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F (2013) EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol 111(1):1\u201310","journal-title":"J Neurooncol"},{"issue":"1","key":"3147_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/1078-0432.CCR-10-1934","volume":"17","author":"MA Elmeliegy","year":"2011","unstructured":"Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF (2011) Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17(1):89\u201399","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3147_CR11","doi-asserted-by":"publisher","first-page":"e201617","DOI":"10.1001\/jamanetworkopen.2020.1617","volume":"3","author":"AW Erickson","year":"2020","unstructured":"Erickson AW, Brastianos PK, Das S (2020) Assessment of effectiveness and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis. JAMA Netw Open 3(3):e201617\u2013e201617","journal-title":"JAMA Netw Open"},{"key":"3147_CR12","first-page":"163","volume-title":"Two-dimensional difference gel electrophoresis: a gel-based proteomic approach for protein analysis molecular toxicology protocols","author":"W Gao","year":"2020","unstructured":"Gao W (2020) Two-dimensional difference gel electrophoresis: a gel-based proteomic approach for protein analysis molecular toxicology protocols. Springer, pp 163\u2013176"},{"issue":"12","key":"3147_CR13","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/ijms19123950","volume":"19","author":"M Garc\u00eda-Aranda","year":"2018","unstructured":"Garc\u00eda-Aranda M, P\u00e9rez-Ruiz E, Redondo M (2018) Bcl-2 inhibition to overcome resistance to chemo-and immunotherapy. Int J Mol Sci 19(12):3950","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3147_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","volume":"21","author":"JE Guikema","year":"2017","unstructured":"Guikema JE, Amiot M, Eldering E (2017) Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opin Ther Targets 21(8):767\u2013779","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"3147_CR15","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.3892\/ol.2017.6591","volume":"14","author":"J Hamamoto","year":"2017","unstructured":"Hamamoto J, Yasuda H, Aizawa K et al (2017) Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. Oncol Lett 14(3):3559\u20133565. https:\/\/doi.org\/10.3892\/ol.2017.6591","journal-title":"Oncol Lett"},{"issue":"2","key":"3147_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i2.40","volume":"22","author":"H Harada","year":"2012","unstructured":"Harada H, Grant S (2012) Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot Gene Expr 22(2):117\u2013129","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"18","key":"3147_CR17","doi-asserted-by":"publisher","first-page":"29558","DOI":"10.18632\/oncotarget.16365","volume":"8","author":"CT Ishida","year":"2017","unstructured":"Ishida CT, Bianchetti E, Shu C et al (2017) BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. Oncotarget 8(18):29558","journal-title":"Oncotarget"},{"issue":"10","key":"3147_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/CAD.0000000000000561","volume":"28","author":"J Jin","year":"2017","unstructured":"Jin J, Xiong Y, Cen B (2017) Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase targeted therapy in lung and gastric cancer. Anticancer Drugs 28(10):1141","journal-title":"Anticancer Drugs"},{"issue":"6","key":"3147_CR19","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.4049\/jimmunol.179.6.3417","volume":"179","author":"TN Jorgensen","year":"2007","unstructured":"Jorgensen TN, McKee A, Wang M et al (2007) Bim and Bcl-2 mutually affect the expression of the other in T cells. J Immunol 179(6):3417\u20133424","journal-title":"J Immunol"},{"issue":"34","key":"3147_CR20","doi-asserted-by":"publisher","first-page":"36456","DOI":"10.18632\/oncotarget.5505","volume":"6","author":"G Karpel-Massler","year":"2015","unstructured":"Karpel-Massler G, B\u00e2 M, Shu C et al (2015) TIC10\/ONC201 synergizes with Bcl-2\/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget 6(34):36456","journal-title":"Oncotarget"},{"issue":"1","key":"3147_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00984-9","volume":"8","author":"G Karpel-Massler","year":"2017","unstructured":"Karpel-Massler G, Ishida CT, Bianchetti E et al (2017) Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat Commun 8(1):1\u201314","journal-title":"Nat Commun"},{"issue":"1","key":"3147_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ijc.20985","volume":"116","author":"F Koizumi","year":"2005","unstructured":"Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K (2005) Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116(1):36\u201344. https:\/\/doi.org\/10.1002\/ijc.20985","journal-title":"Int J Cancer"},{"issue":"5","key":"3147_CR23","doi-asserted-by":"publisher","first-page":"e64051","DOI":"10.1371\/journal.pone.0064051","volume":"8","author":"J Levesley","year":"2013","unstructured":"Levesley J, Steele L, Taylor C, Sinha P, Lawler SE (2013) ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death. PLoS ONE 8(5):e64051","journal-title":"PLoS ONE"},{"issue":"6","key":"3147_CR24","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00204-019-02453-2","volume":"93","author":"Z Liu","year":"2019","unstructured":"Liu Z, Gao W (2019) Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol 93(6):1555\u20131571","journal-title":"Arch Toxicol"},{"issue":"9","key":"3147_CR25","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00204-020-02816-0","volume":"94","author":"Z Liu","year":"2020","unstructured":"Liu Z, Gao W (2020) Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. Arch Toxicol 94(9):3125\u20133136","journal-title":"Arch Toxicol"},{"issue":"3","key":"3147_CR26","doi-asserted-by":"publisher","first-page":"e32895","DOI":"10.1371\/journal.pone.0032895","volume":"7","author":"C Lu","year":"2012","unstructured":"Lu C, Shao C, Cobos E, Singh KP, Gao W (2012) Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS ONE 7(3):e32895","journal-title":"PLoS ONE"},{"issue":"1","key":"3147_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2020.11686","volume":"23","author":"Y Lu","year":"2020","unstructured":"Lu Y, Bian D, Zhang X, Zhang H, Zhu Z (2020) Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Mol Med Rep 23(1):1\u20131","journal-title":"Mol Med Rep"},{"issue":"32","key":"3147_CR28","doi-asserted-by":"publisher","first-page":"33006","DOI":"10.18632\/oncotarget.5026","volume":"6","author":"T Lv","year":"2015","unstructured":"Lv T, Wang Q, Cromie M et al (2015) Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. Oncotarget 6(32):33006","journal-title":"Oncotarget"},{"key":"3147_CR29","first-page":"37","volume-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer Advances in cancer research","author":"S Maji","year":"2018","unstructured":"Maji S, Panda S, Samal SK et al (2018) Bcl-2 antiapoptotic family proteins and chemoresistance in cancer Advances in cancer research, vol 137. Elsevier, pp 37\u201375"},{"key":"3147_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fonc.2018.00176","volume":"8","author":"AD Meedendorp","year":"2018","unstructured":"Meedendorp AD, ter Elst A, t\u2019Hart NA, Groen HJ, Schuuring E, van der Wekken AJ (2018) Response to HER2 inhibition in a patient with brain metastasis With EGFR TKI acquired resistance and an HER2 amplification. Front Oncol 8:176","journal-title":"Front Oncol"},{"issue":"7","key":"3147_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med 376(7):629\u2013640","journal-title":"N Engl J Med"},{"issue":"6","key":"3147_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-018-0526-4","volume":"32","author":"GM O\u2019Kane","year":"2018","unstructured":"O\u2019Kane GM, Leighl NB (2018) Systemic therapy of lung cancer CNS metastases using molecularly targeted agents and immune checkpoint inhibitors. CNS Drugs 32(6):527\u2013542","journal-title":"CNS Drugs"},{"issue":"7","key":"3147_CR33","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK (2017) Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171(7):1678-1691.e13","journal-title":"Cell"},{"issue":"7","key":"3147_CR34","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/1541-7786.MCR-13-0650","volume":"12","author":"F Pareja","year":"2014","unstructured":"Pareja F, Macleod D, Shu C et al (2014) PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res 12(7):987\u20131001","journal-title":"Mol Cancer Res"},{"issue":"22","key":"3147_CR35","doi-asserted-by":"publisher","first-page":"36331","DOI":"10.18632\/oncotarget.16752","volume":"8","author":"MY Park","year":"2017","unstructured":"Park MY, Jung MH, Eo EY et al (2017) Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR\/Cas9-mediated genome editing. Oncotarget 8(22):36331\u201336338. https:\/\/doi.org\/10.18632\/oncotarget.16752","journal-title":"Oncotarget"},{"issue":"1","key":"3147_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000168","volume":"2","author":"VM Patil","year":"2017","unstructured":"Patil VM, Noronha V, Joshi A et al (2017) Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open 2(1):e000168. https:\/\/doi.org\/10.1136\/esmoopen-2017-000168","journal-title":"ESMO Open"},{"issue":"33","key":"3147_CR37","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 36(33):3290","journal-title":"J Clin Oncol"},{"key":"3147_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/LCTT.S119644","volume":"8","author":"M Santarpia","year":"2017","unstructured":"Santarpia M, Liguori A, Karachaliou N et al (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer Targets Ther 8:109","journal-title":"Lung Cancer Targets Ther"},{"issue":"5","key":"3147_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ijc.10096","volume":"97","author":"UA Sartorius","year":"2002","unstructured":"Sartorius UA, Krammer PH (2002) Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97(5):584\u2013592","journal-title":"Int J Cancer"},{"issue":"1","key":"3147_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1593\/neo.121074","volume":"15","author":"A Savry","year":"2013","unstructured":"Savry A, Carre M, Berges R et al (2013) Bcl-2\u2014enhanced efficacy of microtubule-targeting chemotherapy through bim overexpression: implications for cancer treatment. Neoplasia 15(1):49-IN17","journal-title":"Neoplasia"},{"issue":"3","key":"3147_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu Y-L, Hirsh V et al (2016) First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11(3):380\u2013390. https:\/\/doi.org\/10.1016\/j.jtho.2015.11.014","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3147_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.29245\/2578-2967\/2019\/4.1172","volume":"3","author":"E Schwab","year":"2019","unstructured":"Schwab E, Chen JA, Huynh JC et al (2019) Rational strategies for combining Bcl-2 inhibition with targeted drugs for anti-tumor synergy. J Cancer Treat Diagn 3(4):7\u201313","journal-title":"J Cancer Treat Diagn"},{"key":"3147_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-020-06808-2","volume":"20","author":"N Shah","year":"2020","unstructured":"Shah N, Liu Z, Tallman RM et al (2020) Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis. BMC Cancer 20:292","journal-title":"BMC Cancer"},{"issue":"1","key":"3147_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-33784-2","volume":"8","author":"E Shang","year":"2018","unstructured":"Shang E, Zhang Y, Shu C et al (2018) Dual Inhibition of Bcl-2\/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8(1):1\u201311","journal-title":"Sci Rep"},{"issue":"27","key":"3147_CR45","doi-asserted-by":"publisher","first-page":"23058","DOI":"10.18632\/oncotarget.5492","volume":"6","author":"RV Sionov","year":"2015","unstructured":"Sionov RV, Vlahopoulos SA, Granot Z (2015) Regulation of Bim in health and disease. Oncotarget 6(27):23058","journal-title":"Oncotarget"},{"issue":"3","key":"3147_CR46","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/1078-0432.CCR-15-2815","volume":"23","author":"F Skoulidis","year":"2017","unstructured":"Skoulidis F, Papadimitrakopoulou VA (2017) Targeting the gatekeeper: osimertinib in EGFR T790M mutation\u2013positive non\u2013small cell lung cancer. Clin Cancer Res 23(3):618\u2013622","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3147_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ijms20010146","volume":"20","author":"M Takeda","year":"2019","unstructured":"Takeda M, Nakagawa K (2019) First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer? Int J Mol Sci 20(1):146","journal-title":"Int J Mol Sci"},{"issue":"58","key":"3147_CR48","doi-asserted-by":"publisher","first-page":"98771","DOI":"10.18632\/oncotarget.21936","volume":"8","author":"J Tan","year":"2017","unstructured":"Tan J, Li M, Zhong W, Hu C, Gu Q, Xie Y (2017) Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model. Oncotarget 8(58):98771\u201398781. https:\/\/doi.org\/10.18632\/oncotarget.21936","journal-title":"Oncotarget"},{"key":"3147_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdx729.007","volume":"28","author":"J Vansteenkiste","year":"2017","unstructured":"Vansteenkiste J, Reungwetwattana T, Nakagawa K et al (2017) CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study. Ann Oncol 28:189. https:\/\/doi.org\/10.1093\/annonc\/mdx729.007","journal-title":"Ann Oncol"},{"key":"3147_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-016-0268-z","volume":"9","author":"S Wang","year":"2016","unstructured":"Wang S, Cang S, Liu D (2016) Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol 9:34. https:\/\/doi.org\/10.1186\/s13045-016-0268-z","journal-title":"J Hematol Oncol"},{"key":"3147_CR51","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.2147\/IJN.S258699","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Mao W, Wang Z et al (2020) Enhanced anti-brain metastasis from non-small cell lung cancer of osimertinib and doxorubicin co-delivery targeted nanocarrier. Int J Nanomed 15:5491","journal-title":"Int J Nanomed"},{"issue":"11","key":"3147_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21037\/atm.2016.05.48","volume":"4","author":"S Watanabe","year":"2016","unstructured":"Watanabe S, Hayashi H, Nakagawa K (2016) Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? Ann Transl Med 4(11):225","journal-title":"Ann Transl Med"},{"issue":"7","key":"3147_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/JTO.0b013e318219ab87","volume":"6","author":"B Weber","year":"2011","unstructured":"Weber B, Winterdahl M, Memon A et al (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6(7):1287\u20131289. https:\/\/doi.org\/10.1097\/JTO.0b013e318219ab87","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3147_CR54","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11):1359\u20131370. https:\/\/doi.org\/10.1038\/nm.2537","journal-title":"Nat Med"},{"issue":"26","key":"3147_CR55","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"Y-L Wu","year":"2018","unstructured":"Wu Y-L, Ahn M-J, Garassino MC et al (2018) CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 36(26):2702\u20132709","journal-title":"J Clin Oncol"},{"issue":"10","key":"3147_CR56","doi-asserted-by":"publisher","first-page":"S592","DOI":"10.1016\/j.jtho.2018.08.882","volume":"13","author":"L Xing","year":"2018","unstructured":"Xing L, Pan Y, Shi Y et al (2018) P1. 13-25 efficacy and safety of osimertinib in EGFR T790M-positive advanced NSCLC patients with brain metastases (APOLLO study). J Thorac Oncol 13(10):S592","journal-title":"J Thorac Oncol"},{"key":"3147_CR57","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"J Yang","year":"2017","unstructured":"Yang J, Ahn M, Kim D et al (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35:1288\u20131296","journal-title":"J Clin Oncol"},{"issue":"7","key":"3147_CR58","first-page":"1286","volume":"39","author":"S Yoneya","year":"1998","unstructured":"Yoneya S, Saito T, Komatsu Y, Koyama I, Takahashi K, Duvoll-Young J (1998) Binding properties of indocyanine green in human blood. Invest Ophthalmol vis Sci 39(7):1286\u20131290","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"1","key":"3147_CR59","doi-asserted-by":"publisher","first-page":"e0210608","DOI":"10.1371\/journal.pone.0210608","volume":"14","author":"X Yu","year":"2019","unstructured":"Yu X, Dobrikov M, Keir ST et al (2019) Synergistic antitumor effects of 9.2. 27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS ONE 14(1):e0210608","journal-title":"PLoS ONE"},{"issue":"1","key":"3147_CR60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13578-019-0322-y","volume":"9","author":"Y Zhan","year":"2019","unstructured":"Zhan Y, Wang Y, Qi M et al (2019) BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell Biosci 9(1):60","journal-title":"Cell Biosci"},{"issue":"2","key":"3147_CR61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/aps.2016.107","volume":"38","author":"SR Zhang","year":"2017","unstructured":"Zhang SR, Zhu LC, Jiang YP et al (2017) Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin 38(2):233\u2013240. https:\/\/doi.org\/10.1038\/aps.2016.107","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3147_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2519-3","volume":"16","author":"R Zhao","year":"2016","unstructured":"Zhao R, Zhou S, Xia B et al (2016) AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. BMC Cancer 16(1):1\u20138","journal-title":"BMC Cancer"},{"issue":"3","key":"3147_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/bjc.2017.432","volume":"118","author":"L Zhou","year":"2018","unstructured":"Zhou L, Zhang Y, Sampath D et al (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118(3):388\u2013397","journal-title":"Br J Cancer"},{"issue":"1","key":"3147_CR64","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1038\/s41598-017-06632-y","volume":"7","author":"B Zou","year":"2017","unstructured":"Zou B, Lee VHF, Chen L, Ma L, Wang DD, Yan H (2017) Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Sci Rep 7(1):6595. https:\/\/doi.org\/10.1038\/s41598-017-06632-y","journal-title":"Sci Rep"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-021-03147-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T01:04:40Z","timestamp":1675645480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-021-03147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3147"],"URL":"https:\/\/doi.org\/10.1007\/s00204-021-03147-4","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee at West Virginia University in Morgantown, West Virginia (Protocol No. 16404001894).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The interpreted and analyzed data from this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}